BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 17146554)

  • 21. Src kinase-induced phosphorylation of annexin A2 mediates glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Spijkers-Hagelstein JA; Mimoso Pinhanços S; Schneider P; Pieters R; Stam RW
    Leukemia; 2013 Apr; 27(5):1063-71. PubMed ID: 23334362
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Characteristics of fusion gene and immunophenotype in MLL gene rearrangement positive childhood acute lymphoblastic leukemia].
    Gao C; Zhao W; Liu Y; Gong WY; Li WJ; Li ZG; Wu MY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Oct; 17(5):1283-8. PubMed ID: 19840468
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Analyzing acute leukemia patients with complex MLL rearrangements by a sequential LDI-PCR approach.
    Binato R; Meyer C; Macedo-Silva ML; Garcia D; Figueiredo A; Hofmann J; Vieira TP; Abdelhay E; Marschalek R
    Cancer Lett; 2013 Sep; 338(2):249-54. PubMed ID: 23562474
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of CD34+ and CD34- leukemia-initiating cells in MLL-rearranged human acute lymphoblastic leukemia.
    Aoki Y; Watanabe T; Saito Y; Kuroki Y; Hijikata A; Takagi M; Tomizawa D; Eguchi M; Eguchi-Ishimae M; Kaneko A; Ono R; Sato K; Suzuki N; Fujiki S; Koh K; Ishii E; Shultz LD; Ohara O; Mizutani S; Ishikawa F
    Blood; 2015 Feb; 125(6):967-80. PubMed ID: 25538041
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TGFβ1 synergizes with FLT3 ligand to induce chemoresistant quiescence in acute lymphoblastic leukemia with MLL gene rearrangements.
    Tamai M; Furuichi Y; Kasai S; Ando N; Harama D; Goi K; Inukai T; Kagami K; Abe M; Ichikawa H; Sugita K
    Leuk Res; 2017 Oct; 61():68-76. PubMed ID: 28917156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Promoter hypermethylation in MLL-r infant acute lymphoblastic leukemia: biology and therapeutic targeting.
    Schafer E; Irizarry R; Negi S; McIntyre E; Small D; Figueroa ME; Melnick A; Brown P
    Blood; 2010 Jun; 115(23):4798-809. PubMed ID: 20215641
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clofarabine exerts antileukemic activity against cytarabine-resistant B-cell precursor acute lymphoblastic leukemia with low deoxycytidine kinase expression.
    Huang M; Inukai T; Miyake K; Tanaka Y; Kagami K; Abe M; Goto H; Minegishi M; Iwamoto S; Sugihara E; Watanabe A; Somazu S; Shinohara T; Oshiro H; Akahane K; Goi K; Sugita K
    Cancer Med; 2018 Apr; 7(4):1297-1316. PubMed ID: 29473342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of single nucleotide polymorphisms of cytarabine metabolic genes on drug toxicity in childhood acute lymphoblastic leukemia.
    Gabor KM; Schermann G; Lautner-Csorba O; Rarosi F; Erdelyi DJ; Endreffy E; Berek K; Bartyik K; Bereczki C; Szalai C; Semsei AF
    Pediatr Blood Cancer; 2015 Apr; 62(4):622-8. PubMed ID: 25557962
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mixed lineage leukemia-rearranged childhood pro-B and CD10-negative pre-B acute lymphoblastic leukemia constitute a distinct clinical entity.
    Attarbaschi A; Mann G; König M; Steiner M; Strehl S; Schreiberhuber A; Schneider B; Meyer C; Marschalek R; Borkhardt A; Pickl WF; Lion T; Gadner H; Haas OA; Dworzak MN
    Clin Cancer Res; 2006 May; 12(10):2988-94. PubMed ID: 16707593
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Azacitidine successfully maintained the second remission in an infant with KMT2A-rearranged acute lymphoblastic leukemia who relapsed after unrelated cord blood transplantation.
    Chijimatsu I; Imanaka Y; Tomizawa D; Eguchi M; Nishimura S; Karakawa S; Miki M; Hamamoto K; Fujita N
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28675638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Genetic polymorphism of NAD(P)H:quinone oxidoreductase is associated with an increased risk of infant acute lymphoblastic leukemia without MLL gene rearrangements.
    Lanciotti M; Dufour C; Corral L; Di Michele P; Pigullo S; De Rossi G; Basso G; Leszl A; Luciani M; Lo Nigro L; Micalizzi C; Valsecchi MG; Biondi A; Haupt R
    Leukemia; 2005 Feb; 19(2):214-6. PubMed ID: 15618957
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preclinical efficacy of gemcitabine in MLL-rearranged infant acute lymphoblastic leukemia.
    Wander P; Cheung LC; Pinhanҫos SS; Jones L; Kerstjens M; Arentsen-Peters STCJM; Singh S; Chua GA; Castro PG; Schneider P; Dolman MEM; Koopmans B; Molenaar JJ; Pieters R; Zwaan CM; Kotecha RS; Stam RW
    Leukemia; 2020 Nov; 34(11):2898-2902. PubMed ID: 32488115
    [No Abstract]   [Full Text] [Related]  

  • 33. Elevated S100A8/S100A9 expression causes glucocorticoid resistance in MLL-rearranged infant acute lymphoblastic leukemia.
    Spijkers-Hagelstein JA; Schneider P; Hulleman E; de Boer J; Williams O; Pieters R; Stam RW
    Leukemia; 2012 Jun; 26(6):1255-65. PubMed ID: 22282267
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systematic chemical and molecular profiling of MLL-rearranged infant acute lymphoblastic leukemia reveals efficacy of romidepsin.
    Cruickshank MN; Ford J; Cheung LC; Heng J; Singh S; Wells J; Failes TW; Arndt GM; Smithers N; Prinjha RK; Anderson D; Carter KW; Gout AM; Lassmann T; O'Reilly J; Cole CH; Kotecha RS; Kees UR
    Leukemia; 2017 Jan; 31(1):40-50. PubMed ID: 27443263
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemosensitivity is differentially regulated by the SDF-1/CXCR4 and SDF-1/CXCR7 axes in acute lymphoblastic leukemia with MLL gene rearrangements.
    Ando N; Furuichi Y; Kasai S; Tamai M; Harama D; Kagami K; Abe M; Goi K; Inukai T; Sugita K
    Leuk Res; 2018 Dec; 75():36-44. PubMed ID: 30453100
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lineage Switch in MLL-Rearranged Infant Leukemia Following CD19-Directed Therapy.
    Rayes A; McMasters RL; O'Brien MM
    Pediatr Blood Cancer; 2016 Jun; 63(6):1113-5. PubMed ID: 26914337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Complex MLL rearrangement in non-infiltrated bone marrow in an infant with stage II precursor B-lymphoblastic lymphoma.
    Ahlmann M; Meyer C; Marschalek R; Burkhardt B; Koehler G; Klapper W; Juergens H; Rossig C
    Eur J Haematol; 2014 Oct; 93(4):349-53. PubMed ID: 24635731
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MEK inhibition is a promising therapeutic strategy for MLL-rearranged infant acute lymphoblastic leukemia patients carrying RAS mutations.
    Kerstjens M; Driessen EM; Willekes M; Pinhanços SS; Schneider P; Pieters R; Stam RW
    Oncotarget; 2017 Feb; 8(9):14835-14846. PubMed ID: 27588400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Network-based expression analysis reveals key genes related to glucocorticoid resistance in infant acute lymphoblastic leukemia.
    Mousavian Z; Nowzari-Dalini A; Stam RW; Rahmatallah Y; Masoudi-Nejad A
    Cell Oncol (Dordr); 2017 Feb; 40(1):33-45. PubMed ID: 27798768
    [TBL] [Abstract][Full Text] [Related]  

  • 40. K-Ras mutations and N-Ras mutations in childhood acute leukemias with or without mixed-lineage leukemia gene rearrangements.
    Liang DC; Shih LY; Fu JF; Li HY; Wang HI; Hung IJ; Yang CP; Jaing TH; Chen SH; Liu HC
    Cancer; 2006 Feb; 106(4):950-6. PubMed ID: 16404744
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.